Literature DB >> 19350450

The relationship of neonatal subclinical electrographic seizures to neurodevelopmental outcome at 1 year of age.

Semra Hiz Kurul1, Sumer Sutcuoglu, Uluc Yis, Nuray Duman, Abdullah Kumral, Hasan Ozkan.   

Abstract

OBJECTIVE: To evaluate the influence of 'only electroencephalographic (EEG)' and 'EEG plus clinical' seizures during neonatal period on neurodevelopment of the infants. PATIENTS AND METHODS: The long-term digital-video- EEG tracings of the first 3 days of life of 30 neonates were assessed. The babies were subdivided into three groups: Group 1 had neither EEG nor clinical seizures. Group 2 had EEG seizures but no clinical seizures. Group 3 experienced both EEG and clinical seizures. The groups were compared in regard to psychomotor retardation and epilepsy at corrected age of 1 year.
RESULTS: The mean birthweight was 1952.50 +/- 978.74 (685-4103) g. The mean gestational age was 32.53 +/- 4.26 (24-40) weeks. In regard to sex, gestational age and birth weight, there was no significant difference between the three groups. Ten percent of newborns in Group 1 and 53.8% of newborns in Group 3 had psychomotor retardation. No babies in Group 2 experienced psychomotor retardation. The differences between the Groups 1 and 3 and Groups 2 and 3 were found statistically significant. Only one baby in Group 3 had epilepsy. In Groups 1 and 2, no babies had epilepsy. The differences between the groups were not significant.
CONCLUSION: Neonatal seizures, but not silent EEG seizures are in relationship with poor neurodevelopmental outcome evaluated at corrected age of 1 year in newborns.

Entities:  

Mesh:

Year:  2009        PMID: 19350450     DOI: 10.1080/14767050902801736

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  1 in total

1.  A novel approach to the study of hypoxia-ischemia-induced clinical and subclinical seizures in the neonatal rat.

Authors:  M Cuaycong; M Engel; S L Weinstein; E Salmon; J M Perlman; S Sunderam; S J Vannucci
Journal:  Dev Neurosci       Date:  2011-09-27       Impact factor: 2.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.